CN-121971458-A - Application of gastrodin in preparation of medicine for improving acute enteritis combined with cognitive dysfunction

Abstract

The invention discloses application of gastrodin in preparation of a medicine for improving acute enteritis and cognitive dysfunction. According to the invention, the acute enteritis combined cognitive dysfunction mouse model is induced and constructed by Dextran Sodium Sulfate (DSS), and a gastrodin intervention is given in a gastric lavage mode, so that a remarkable improvement effect is achieved on the aspects of behaviours, intestinal pathology, intestinal barrier, inflammatory regulation, intestinal microecology, metabonomics, proteomics and the like. The gastrodin in the invention is used as a single active ingredient, plays a role through a synergistic regulation network of intestinal microecology-intestinal barrier-inflammatory regulation-intestinal tract-brain axis-central nervous function, simultaneously realizes double effects of acute enteritis pathological repair and depression-like behavior improvement, has obvious improvement effect, has definite action mechanism, controllable dosage and good biocompatibility, provides a brand-new active substance and application scheme for intervention of combining cognitive dysfunction of acute enteritis, and can be used for preparing related medicines.

Inventors

• SONG JIALIN
• ZHOU XIAOYAN
• LIU YAN
• WU RUICONG
• SUN RUI
• GAO YAXIN
• XIE YANJIE
• XIE JIESHAN

Assignees

• 徐州医科大学

Dates

Publication Date

20260505

Application Date

20260320

Claims (7)

1. 1. Application of gastrodin in preparing medicine for improving acute enteritis complicated with cognitive dysfunction is provided.
2. 2. The use of gastrodin according to claim 1 for the preparation of a medicament for improving acute enteritis combined with cognitive dysfunction, wherein the acute enteritis combined with cognitive dysfunction is dextran sodium sulfate induced acute enteritis combined with cognitive dysfunction.
3. 3. The application of gastrodin in preparing a medicament for improving acute enteritis combined cognitive dysfunction according to claim 2 is characterized in that the medicament has one or more functions of (1) improving depression-like behaviors of an acute enteritis combined cognitive dysfunction model animal, (2) repairing intestinal pathological damages of the acute enteritis combined cognitive dysfunction model animal, (3) repairing intestinal barriers of the acute enteritis combined cognitive dysfunction model animal, (4) inhibiting inflammatory factor expression of intestinal tracts of the acute enteritis combined cognitive dysfunction model animal, (5) regulating intestinal flora structure and diversity of the acute enteritis combined cognitive dysfunction model animal, (6) improving intestinal metabolite spectrum of the acute enteritis combined cognitive dysfunction model animal, and (7) regulating key protein expression of intestinal tracts of the acute enteritis combined cognitive dysfunction model animal.
4. 4. The use of gastrodin according to claim 1 or 2 in the manufacture of a medicament for improving acute enteritis combined with cognitive dysfunction, characterized in that the medicament consists of an active ingredient gastrodin and pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials are one or more of starch, lactose, microcrystalline cellulose, polyethylene glycol, magnesium stearate and hypromellose.
5. 5. The use of gastrodin according to claim 4 for the preparation of a medicament for improving acute enteritis combined with cognitive dysfunction, characterized in that the dose of gastrodin is 240mg/kg.
6. 6. The use of gastrodin according to claim 4 for the preparation of a medicament for improving acute enteritis combined with cognitive dysfunction, characterized in that the gastrodin is a gastrodin small molecular monomer with purity not less than 98%.
7. 7. The use of gastrodin according to claim 4 for the preparation of a medicament for improving acute enteritis combined with cognitive dysfunction, wherein the medicament is a powder, a tablet, a granule, a capsule, a solution, a suspension, an emulsion or a lyophilized preparation.

Description

Application of gastrodin in preparation of medicine for improving acute enteritis combined with cognitive dysfunction Technical Field The invention relates to the technical field of biological medicines, in particular to application of gastrodin in preparation of a medicine for improving acute enteritis combined with cognitive dysfunction. Background Inflammatory bowel disease is a disease characterized by chronic, non-specific inflammation of the intestinal tract, wherein acute enteritis is caused by acute onset, severe symptoms (abdominal pain, diarrhea, bloody stool, etc.), and seriously affects the quality of life of patients. The incidence of acute enteritis in the world has been continuously rising in recent years, and has become an important public health problem. It is worth noting that there is a close co-morbid association between acute enteritis and cognitive dysfunction, and this association is mediated by the "intestinal-brain axis" to form a vicious circle, wherein the destruction of intestinal barrier and inflammatory factor leakage caused by acute enteritis can influence the central nervous system through blood circulation or nerve pathways to induce depression-like behavior, while depression can be activated through hypothalamus-pituitary-adrenal (HPA) axis to release cortisol and other hormones, further aggravate intestinal inflammation and barrier injury, and result in poor prognosis. Clinical data show that the incidence rate of cognitive dysfunction of patients with acute enteritis is far higher than that of common people, and the co-disease phenomenon becomes a key bottleneck for restricting the treatment effect and life quality of patients. The current intervention strategy for combining acute enteritis with cognitive dysfunction still adopts a mode of 'symptomatic separation', has obvious limitations that the treatment of acute enteritis depends on aminosalicylic acid (such as mesalamine) and glucocorticoid medicaments, can temporarily relieve intestinal inflammation, but has the defects of strong side effects (such as osteoporosis and immunosuppression caused by glucocorticoid), easy recurrence and incapacity of repairing intestinal barrier and dysbacteriosis, and the treatment of cognitive dysfunction takes antidepressant medicaments such as selective 5-hydroxytryptamine reuptake inhibitor (SSRI) and the like as the main treatment, but has limited curative effect in the enteritis background, can not improve core pathological injuries such as intestinal inflammation, barrier dysfunction and the like, and can only relieve partial neuropsychiatric symptoms. More seriously, when the two drugs are combined, the metabolic burden of the organism and the potential drug interaction risk are increased (for example, the gastrointestinal reaction can be aggravated by the combination of SSRI and glucocorticoid), and the treatment compliance is further reduced. Therefore, the development of an intervention substance which can simultaneously target intestinal inflammation repair and depression-like behavior improvement, has mild action and strong synergism becomes a technical problem to be solved in clinic. Gastrodin (gastrodin, GAS) is a natural active ingredient extracted from rhizoma Gastrodiae, and has chemical name of 4-hydroxymethyl phenyl-beta-D-glucopyranoside, and has been used for adjuvant treatment of migraine, neurasthenia, cerebrovascular diseases, etc. However, no relevant report of gastrodin for improving acute enteritis and cognitive dysfunction exists at present. Disclosure of Invention The invention aims to provide application of gastrodin in preparation of a medicine for improving acute enteritis complicated with cognitive dysfunction, and aims to solve the technical problems of 'symptomatic separation, strong side effect and poor synergy' of the existing acute enteritis complicated with cognitive dysfunction intervention scheme. In order to achieve the purpose, the application of the gastrodin in preparing the medicine for improving the acute enteritis and the cognitive dysfunction is realized through the following technical scheme. Further, the acute enteritis and cognitive dysfunction is acute enteritis and cognitive dysfunction induced by dextran sulfate. Further, the medicament has one or more of the following functions: (1) The depression-like behavior of the model animal combining the acute enteritis with the cognitive dysfunction is improved by increasing the autonomous activity capacity and exploration willingness of the model animal, reducing the anxiety state, relieving the core depression phenotype and comprehensively improving the emotion and behavior abnormality caused by the common diseases; (2) The intestinal pathological damage of the animal with the model of the acute enteritis combined with the cognitive dysfunction is obviously recovered, the colon length reduction caused by the acute enteritis is obviously recovered, the pathological changes of intestinal t